IGF-I: from diagnostic to triple-helix gene therapy of solid tumors

• Autorzy: Trojan L. A. , Kopinski P. , Wei M.X. , Ly A. , Glogowska A. , Czarny J. , Shevelev A. , Przewlocki R. , Henin D. , Trojan J.
• Języki publikacji: EN

Abstrakty

EN

Alterations in the expression of growth factors and their receptors are associated with the growth and development of human tumors. One such growth factor is IGF-I (insulin-like growth factor I), a 70-amino-acid polypeptide expressed in many tissues, including brain. IGF-I is also expressed at high levels in some nervous system-derived tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 dif­ferent tumors are considered as expressing the IGF-I gene. Malignant glioma, the most common human brain cancer, is usually fatal. Average survival is less than one year. Our strategy of gene therapy for the treatment of gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression as a differential marker, and 2) application of "triple-helix anti-IGF-I " therapy. In the latter approach, tumor cells are transfected with a vector, which encodes an oligoribonucleotide — an RNA strand containing oligopurine sequence which might be capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix). Human tumor cells transfected in vitro become down-regulated in the production ofm IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic characteristics. Similar results were obtained when IGF-I antisense strategy was applied. In both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit tumor specific immunity which leads to elimination of established tumors.

Słowa kluczowe

EN

gene therapy; triple-helix; malignant glioma; glioblastoma; alteration; man; brain cancer; development; growth factor; tumour; solid tumour

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2002
• Tom: 49
• Numer: 4
• Opis fizyczny: p.979-990,fig.

Twórcy

autor

Trojan L. A.

• Medical University, M.Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland

autor

Kopinski P.

autor

Wei M.X.

autor

Ly A.

autor

Glogowska A.

autor

Czarny J.

autor

Shevelev A.

autor

Przewlocki R.

autor

Henin D.

autor

Trojan J.

Bibliografia

• Abelev GJ. (1971) Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res.; 14: 295-9.
• Adamo M, Koval A, Le Roith D, Roberts C. (1994) Posttranscriptional regulation of IGF-I gene expression. In The insulin­like growth factors and their regulatory proteins. Baxter RC, Rosenfeld RG, eds, pp 23-31. Elsevier, New York.
• Adams TE, Epa VC, Garrett TP, Ward CV. (2000) Structure and function of the type I insulin-like growth factor receptor. CellMolLife Sci.; 57: 1050-93.
• Aggarwal B, Schwarz L, Hogan M, Rando R. (1996) Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF dependent growth of human glioblastoma tumor cells. Cancer Res.; 56: 5156- 64.
• Alunni-Fabbroni M, Pirolli D, Manzini G, Xodo L. (1996) (A,G)-oligonucleotides form extraordinary stable triple helices with a critical RY sequence of the murine c-Ki- ras promotor and inhibit transcription in transfected NIH 3T3 cells. Biochemistry.; 35: 16361-9.
• Angelisova P, Cerny J, Horejsi V. (1996) Association of the putative B-lymphocyte surface molecule B7.3 with a protein kinase activity. Biochem Biophys Res Commun.; 228: 489-93.
• Anthony D, Pan Y, Wu S, Guo Y. (1998) Ex vivo and in vivo IGF-I antisense RNA strategies for treatment of cancers in humans. Adv Exp Med Biol.; 451: 27-34.
• Antoniades HN, Galanopoulis T, Nevile-Golden J, Maxwell M. (1992) Expression of insulin-like growth factor I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: In vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer.; 50: 215-22.
• Ayer-le-Lievre C, Stahlbom PA, Sara VR. (1991) Expression of IGF-I and -II mRNA in the brain and craniofacial region of the rat fetus. Development.; 111: 105-15.
• Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alu M, Della TS, Alberti D, Buzzoni R. (2002) A randomised, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer.; 94: 299-304.
• Baserga R. (1994) Oncogenes and strategy of growth factors. Cell.; 79: 927-30.
• Baserga R. (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res.; 55: 249-52.
• Baserga R, Sell C, Porcu P, Rubini M. (1994) The role of the IGF-I receptor in the growth and transformation of mammalian cells. CellProlif.; 27: 63-71.
• Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. (1992) Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci US A.; 89: 3488-92.
• Bustin SA, Dorudi S, Phillips SM, Feakins RM, Jenkins PJ. (2002) Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol.; 23: 130-8.
• Campbell MJ, Woodside JV, Secker-Walker J, Titcomb A, Leathem AJ. (2001) IGF status is altered by tamoxifen in patients with breast cancer. Mol Pathol.; 54: 307-10.
• Chan PR, Glazer RM. (1997) Triplex DNA: fundamentals, advances and potential applications for gene therapy. J Mol Med.; 75: 267-82.
• Chen L, Ashe S, Brady WA, Hellstrom KE, Ledbetter IA, Mc Growan P, Linsley PS. (1992) Costimulation of anti-tumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell.; 71: 1093-102.
• Collet C, Candy J. (1998) How many insulin-like growth factor binding proteins? Mol Cell Endocrinol.; 139: 1-6.
• D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. (1996) A soluble insulin-like growth factor receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res.; 56: 4013-20.
• Daughaday WH, Rotwein P. (1989) Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev.; 10: 68-91.
• Daughaday WH, Hall K, Raben MS, Salmon WD, Van den Brande JL, Wyk JI. (1972) Somatomedin: proposed designation for sulphation factor. Nature.; 235: 107.
• Dervan P. (1992) Reagents for the site-specific cleavage of megabase DNA. Nature.; 359: 87-8.
• D'Mello S, Galli C, Ciotti T, Calissano P. (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by IGF-I and cAMP. Proc Natl Acad Sci U S A.; 90: 10989-93.
• Durland R, Kessler D, Gunnell S, Duvic M, Petit B, Hogan M. (1991) Binding of triple helix forming oligonucleotides to sites in gene promoters. Biochemistry.; 30: 9246-55.
• Ebbinghaus S, Gee J, Rodu B, Mayfield C, Sanders G, Miller D. (1993) Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest.; 92: 2433-9.
• Ellouk-Achard S, Djenabi S, De Oliveira GA, Desauty G, Duc HT, Zohar M, Trojan J, Claude JR, Sarasin A, Lafarge- Frayssinet C. (1998) Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA. J Hepatol.; 29: 807-18.
• Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M. (2002) IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content. Eur J Endocrinol.; 146: 813-21.
• Freeman GB, Gray GS, Gimmi CD, Lombard DB, Zhou L-I, White M, Fingeroth JD, Gribben JG, Nadler LM. (1991) Structure, expression and T cell costimulator activity of murine homologue of the human B lymphocyte activation antigen B7. J Exp Med.; 174: 625-31.
• Froesch CS, Schwander J, Zapf J. (1985) Actions of insulin-like growth factors. Annu Rev Physiol.; 47:443-67.
• Giovannangeli C, Helene C. (1997) Progress in developments of triplex-based strategies. Antisense Nucleic Acid Drug Dev.; 7: 413-21.
• Giovanucci E. (1999) Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res.; 51: 34-41.
• Giovanucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Rev.; 9: 345-9.
• Green PJ, Pines O, Inouye M. (1986) The role of antisense RNA in gene regulation. Annu RevBiochem.; 55: 569-97.
• Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M-S. (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science.; 263: 518-20.
• Han VKM, D'Ercole A, Lund PK. (1987) Cellular localization of somatomedin (insulin-like growth factor) message RNA in human fetus. Science.; 236: 193-7.
• Harding F, Mc Arthur JG, Gross JA, Raulet DH, Allison JP. (1992) CD28-mediated and signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature.; 356:607- 9.
• Heldin CH, Westermark B. (1989) Growth factors as transforming proteins. Eur J Biochem.; 184: 487-96.
• Helene C. (1994) Control of oncogene expression by antisense nucleic acids. Eur J Cancer.; 30A: 1721-6.
• Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lonning PE. (2001) Plasma insulin-like growth binding protein-3 proteolysis is increased in primary breast cancer. Br J Cancer.; 85: 74-7.
• Hva V, Oh Y, Rosenfeld RG. (1999) The insulin-like growth factor-binding protein superfamily. Endocr Rev.; 20: 761-87.
• Jansen M, van Schaik FM, Ricker AT, Bullock B, Woods DE, Gabbay KH, Nussbaum AL, Sussenbach JS, Van den Brande JL. (1983) Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature.; 306: 609-11.
• Johnson TR, Trojan J, Rudin SD, Blossey BK, Ilan J. (1991) Effects on actinomycin D and cycloheximide on transcript levels of IGF-I, actin and albumin in hepatocyte primary cultures treated with growth hormone and insulin. Mol Reprod Dev.; 30: 95-9.
• Jones JI, Clemmons DR. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev.; 16: 3-34.
• Kiess W, Lee L, Graham DE, Greenstein L, Tseng LY, Rechler MM, Nissley SR. (1989) Rat C6 glial cells synthesize insulin-like growth factor I (IGF-I) and express IGF-I receptors and IGF-II/mannose 6-phosphate receptors. Endocrinology.; 124: 1727-36.
• Lafarge-Frayssinet C, Sarasin A, Duc HT, Frayssinet C, Anthony D, Guo Y, Trojan J. (1997) Gene therapy for hepatocarcinoma: antisense IGF-I transfer into a rat hepatoma cell line inhibits tumorigenesis into syngeneic animal. Cancer Gene Ther.; 4: 276-85.
• Lee DY, Kim SJ, Lee YC. (1999) Serum insulin-like growth factor (IGF-I) and IGF-binding proteins in lung cancer patients. J Korean Med Sci.; 14: 401-4.
• Le Roith D, Bondy C, Yakar S, Liu J, Butler A. (2001) The somatomedin hypothesis. Endocr Rev.; 22: 53-74.
• Linsley PS, Clark EA, Ledbetter JA. (1990) T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/13. Proc Natl Acad Sci US A.; 87: 5031-5.
• Ly A, Duc HT, Kalamarides M, Trojan LA, Pan Y, Shevelev A, Francois J-C, Noel T, Kane A, Henin D, Anthony D, Trojan J. (2001) Human glioma cells transformed by IGF-I triple-helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. MolPathol.; 54: 230-9.
• Ly A, Francois JC, Duc HT, Upegui-Gonzalez LC, Bedel C, Henin D, Bout D, Trojan J. (2000) IGF-I triple helix technology changes tumorigenicity of embryonal carcinoma cells by immune and apoptotic effects. Life Sciences.; 68: 307-9.
• Maher III LJ. (1996) Prospects for the therapeutic use of antigene oligonucleotides. Cancer Invest:.; 14: 66-82.
• Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C. (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer.; 83: 15-7.
• Matthew L, Saiter B, Bhardwag N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTL. Nature.; 392: 86-9.
• Mayfield C, Ebbinghaus S, Gee I, Jones D, Rodu B, Squibb M, Miller D. (1994) Triplex formation by the human Ha-ras promoter inhibits Spl binding and in vitro transcription. J Biol Chem.; 269: 18232-8.
• Mishra L, Bass B, Ooi BS, Sidawy A, Korman L. (1998) Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res.; 8: 473-9.
• Mita K, Nakahara M, Usui T. (2000) Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int J Urol.; 7: 321-9.
• Muta K, Krantz S. (1993) Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin­like growth factor I as well as erytropoietin. J Cell Physiol.; 156: 264-71.
• Olchovsky D, Shimon I, Goldberg I, Shulimzon T, Lubetsky A, Yerllin A, Pariente C, Karasik A, Kanety H. (2002) Elevated insulin-like growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion. Acta Oncol.; 41: 182-7.
• Pollak M. (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer.; 36: 1224-8.
• Porumb H, Gousset H, Letellier R, Salle V, Briane D, Vassy J, Amor-Gueret M, Israel L, Taillandier E. (1996) Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. Cancer Res.; 56: 515-22.
• Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone SD, Baserga R. (1994) Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type-1 IGF-I receptor. Cancer Res.; 54: 48-4850.
• Rininsland F, Johnson T, Chernicky C, Schulze E, Burfeind R, Ilan J. (1997) Suppression of insulin-like growth factor type 1 receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci US A.; 94: 5854-9.
• Rodriguez-Tarduchy G, Collins MKL, Garcia I, Lopez-Rivas A. (1992) Insulin-like growth factor-I inhibits apoptosis in IL- 3-dependent hemopoietic cells. J Immunol.; 149: 535-40.
• Rosen CJ. (1999) Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clin Chem.; 45: 1384-90.
• Rubin R, Baserga R. (1995) Biology of disease. Insulin-like growth factor I receptor. Its role in cell proliferation, apoptosis and tumorigenicity. Lab Invest.; 73: 311-31.
• Rubenstein JL, Nicolas JF, Jacob F. (1984) L'ARN non sens (nsARN): un outil pour inactiver specifiquement l'expression d'un gene donne in vivo. C.R Acad Sci III; 299: 271-4.
• Saji M, Moriarty J, Ban T, Singer D, Kohn L. (1992) Major histocompatibility complex class I gene expression in rat thyroid cells is regulated by hormones, methimazole and iodide as well as interferon. J Clin EndocrinolMetab.; 75: 871-8.
• Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. (1998) The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett.; 93: 114-9.
• Satoh J, Lee YB, Kim SU. (1995) T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res.; 704: 92-6.
• Schwartz RH. (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BBI in interleukin-2 production and immunotherapy. Cell.; 71:1065-8.
• Sell C, Rubini M, Rubin R, Liu J, Efstratiadis A, Baserga R. (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-l IGF-I receptor. Proc Natl Acad Sci U S A.; 90: 11217-21.
• Shevelev A, Burfeind P, Schulze E, Rininsland F, Johnson T, Trojan J, Chernicky C, Helene C, Ilan Ju, Ilan J. (1997) Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model. Cancer Gene Ther.; 4: 105-12.
• Steenbergh PH, Koonen-Reemst AM, Cleutjens CB, Sussenbach JS. (1991) Complete nucleotide sequence of the high molecular weight human IGF-I mRNA. Biochem Biophys Res Commun.; 175: 507-14.
• Sussenbach JS, Steenbergh PH, Holthuizen P. (1992) Structure and expression of the human insulin-like growth factor genes. Growth Regul.; 2: 1-9.
• Trojan J, Blossey B, Johnson T, Rudin S, Tykocinski M, Ilan J. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisens cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci US A.; 89: 4874-8.
• Trojan J, Duc H, Upegui-Gonzalez L, Hor F, Guo Y, Anthony D, Ilan J. (1996) Presence of MHC I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett.; 212: 9-12.
• Trojan J, Johnson T, Rudin S, Blossey B, Kelley K, Shevelev A, Abdul-Karim F, Anthony D, Tykocinski M, Ilan Ju, Ilan J. (1994) Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and II in immunogenicity and differentiation. Proc Natl Acad Sci U S A.; 91: 6088-92.
• Trojan J, Johnson TR, Rudin SD, Ilan Ju, Tykocinski ML, Ilan J. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science.; 259: 94-7.
• Trojan J, Uriel J. (1979) Localization of alpha fetoprotein and serum albumin in the rat central nervous system during fetal and post-natal period. CR Acad Sci Paris.; 289: 1157-60 (in French).
• Upegui-Gonzalez LC, Duc HT, Buisson Y, Arborio M, Lafarge-Frayssinet C, Jasmin C, Guo Y, Trojan J. (1998) Use of the IGF-I antisense strategy in the treatment of the hepatocarcinoma. Adv Exp Med Biol.; 451: 35-42.
• Upegui-Gonzalez LC, Ly A, Sierzega M, Jarocki P, Trojan LA, Duc HT, Pan Y, Shevelev A, Henin D, Anthony D, Nowak W, Popiela T, Trojan J. (2001) IGF-I triple helix strategy in hepatoma treatement. Hepatogastroenterology.; 48: 660-66.
• Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology.; 57: 330-40.
• Valentinis B, Porcu PL, Quinn K, Baserga R. (1994) The role of IGF-I receptor in the transformation by Simian virus 40 T antigen. Oncogene.; 9: 825-31.
• Vasquez KM, Wilson JH. (1998) Triplex-directed modification of genes and gene activity. Trends Biochem Sci.; 23: 4-9.
• Weintraub H, Izant JG, Harland RM. (1985) Antisense RNA as a molecular tool for genetic analysis. Trends Genet.; 1: 23-5.
• Werner H, Le Roith D. (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci.; 57: 932-42.
• Wongkajornslip A, Ouyprasertkul M, Sangruchi T, Huabprasert S, Pan Y, Anthony D. (2001), J Med Assoc Thai.; 84: 740-7.
• Wolk A, Anderson SO, Mantzoros CS, Trichopoulos D, Adami HO. (2000) Can measurements of IGF-I and IGFBP-3 improve the sensitivity of prostate cancer screening? Lancet.; 356: 1902-3.
• Wu Y, Yakar S, Zhao L, Hennighausen L, Le Roith D. (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res.; 62: 1030-5.
• Yu H, Robin T. (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst.; 92: 1472-89.
• Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst.; 91: 151-6.
• Zumkeller W. (2002) IGFs and IGF-binding proteins as diagnostic markers and biological modulators in brain tumors. Expert Rev Mol Diagn.; 2: 473-7.
• Zumkeller W, Westphal M. (2001) The IGF/IGFBP system in CNS malignancy. Mol. Pathol.; 54: 227-9.